Stiris Research’s CEO Selected for Elite Ivey Program
Stiris Research Inc. is pleased to announce that Shantal Feltham, President & CEO has been selected to participate in the 2016 QuantumShift program. QuantumShift is an exclusive invitation-only leadership development program for 40 of Canada’s most promising entrepreneurs. Founded by KPMG Enterprise and the Richard Ivey School of Business at Western University, QuantumShift uses Ivey’s highly regarded case study method and award-winning faculty to help take the skills and talents of these entrepreneurs to the next level.
For more information about QuantumShift, please visit www.quantumshift.ca
STIRIS RESEARCH INC.
Stiris Research is making a difference by collaborating for successful drug approvals.
Stiris Research is an entrepreneurial Clinical Trial Management Company providing clinical study management solutions to biotechnology companies for the execution of complex Phase I-IIIB clinical trials. We work with our clients to provide customized solutions based on individual needs and resource requirements.
Stiris Research is the recipient of the PROFIT HOT 50 award, a ranking of Canada’s most promising businesses, the PROFIT W100 award, ranking Canada’s Top Women Entrepreneurs, the PROFIT 500 award, the definitive ranking of Canada’s Fastest-Growing Companies and the 2011 London Chamber of Commerce Small Business of the Year award.
“The invitation to participate in the QuantumShift program is a tremendous opportunity for me to interact with an elite group of business leaders,” said Shantal Feltham. “I look forward to sharing ideas and learning from both the course materials and my colleagues. This is a great stepping stone to help me take our business to the next level.”
About Stiris Research
Stiris Research is an entrepreneurial Clinical Trial Management company specializing in conducting complex Phase I through IIIB trials for North American biotechnology and biopharmaceutical companies, with a focus on Oncology, CNS and Neurology. Stiris Research was formed as a result of listening to the stakeholders engaged in clinical trials, identifying their unmet needs, and developing a unique, value-based approach to address those needs.
For more information, please contact: